Search the Site
Follow TheCancerLetter on Twitter
join our mailing list

Enter your name and email address to receive an update when we post new content.

IP Login


The Cancer Letter Inc.
PO Box 9905
DC 20016
Tel: 202-362-1809
Fax: 202-379-1787
publication date: Jun 2, 2016
May 2016 PDF

  Multiple Myeloma

Study: Combination of ASCT and Bortezomib
Can Increase Survival

Early findings from a phase III clinical trial showed that patients with multiple myeloma who received an autologous stem cell transplant survived longer without disease progression than those who received only chemotherapy using novel agents.

The study was the largest reported aimed at comparing ASCT with a bortezomib-based regimen alone in patients younger than 65, and will be presented at this year’s annual meeting of the American Society of Clinical Oncology, June 3-7 in Chicago.

“Even in an age of novel therapies, proven approaches can retain their value. This study demonstrated that combining the best of both worlds—initial therapy with a novel agent followed by stem cell transplant—resulted in the best patient outcomes,” said ASCO President Julie Vose in a statement.

      Colorectal Cancer

    Cancers Originating on Left Side of Colon
    Associated with Longer Survival, Study Says

    A retrospective analysis found that the location of the primary tumor within the colon predicts survival and may help inform optimal treatment selection for patients with metastatic colorectal cancer.

    The data show that patients whose primary tumors originate on the left side of the colon—including the descending colon, sigmoid colon and rectum—survive significantly longer than those whose tumors originate on the right side, or the cecum and ascending colon.

    Researchers retrospectively evaluated data from the phase III CALGB/SWOG 80405 clinical trial, a federally funded clinical trial designed to compare Avastin (bevacizumab) and Erbitux (cetuximab) in combination with chemotherapy as initial therapy for metastatic colorectal cancer.

      Drugs and Targets

    FDA Approves Tecentriq, Opdivo, Imbruvica and Lenvima

    FDA granted accelerated approval to Tecentriq (atezolizumab) for urothelial carcinoma, the most common type of bladder cancer. This is the first product in its class of PD-1/PD-L1 inhibitors approved to treat this type of cancer, according to the drug’s sponsor, Genentech.

    Tecentriq is approved for the treatment of patients with locally advanced or metastatic urothelial carcinoma whose disease has worsened during or following platinum-containing chemotherapy, or within 12 months of receiving platinum-containing chemotherapy, either before or after surgical treatment.


        Non-Small Cell Lung Cancer

      Phase Ib Trial Shows 40 Percent of Patients
      Receiving Keytruda Alive After 36-Month Follow Up



      WT1 Vaccine Doubles PFS in Phase II Trial


      Breast Cancer

      LEE011 Meets Primary Endpoint, Improves PFS
      in Phase III Trial


      Precision Medicine

      Study: Precision Medicine Yields Better
      Outcomes in Phase I Clinical Trials


      Palliative Care

      Study: Early Palliative Care Provides Benefits
      for Family Caregivers of Patients


      NCI CTEP-Approved Trials for the Month of May

      Copyright (c) 2016 The Cancer Letter Inc.